AstraZeneca is contemplating relocating its stock listing from the London Stock Exchange to the US, reflecting dissatisfaction with the UK investment climate. The company has a market value of £157 billion and has already made significant investments in the US, including £39 billion last year related to the Covid vaccine. CEO Sir Pascal Soriot has cited the need for improved incentives in Europe to retain jobs and investments, while recent actions, such as halting the expansion of a Liverpool plant, illustrate concerns over government support. Analysts warn this move could signal a trend among other firms considering similar relocations.
Sir Pascal Soriot has repeatedly highlighted the need for Europe to enhance its incentives for new medicines, warning that jobs could relocate to the US if these conditions remain unchanged.
AstraZeneca's recent decision to pause a £450 million investment in expanding its Liverpool flu vaccine plant underscores its dissatisfaction with the UK government's financial support provisions.
Collection
[
|
...
]